Table 2.
Children’s Oncology Group (COG) neuroblastoma risk assignment table [34].
| INSS Stage * | Age | MYCN | DNA Index | INPC | Other | Risk Classification |
|---|---|---|---|---|---|---|
| 1 | Any | Any | Any | Any | Low | |
| 2a/2b | Any | Not amplified | Any | Any | Resection ≥50%, asymptomatic | Low |
| 2a/2b | Any | Not amplified | Any | Any | Resection ≥50%, symptomatic | Intermediate |
| 2a/2b | Any | Not amplified | Any | Any | Resection <50% | Intermediate |
| 2a/2b | Any | Not amplified | Any | Any | Biopsy only | Intermediate |
| 2a/2b | Any | Amplified | Any | Any | Any degree of resection | High |
| 3 | <547 days | Not amplified | Any | Any | Intermediate | |
| 3 | >547 days | Not amplified | Any | Favorable | Intermediate | |
| 3 | Any | Amplified | Any | Any | High | |
| 3 | >547 days | Not amplified | Any | Unfavorable | High | |
| 4 | <365 d | Amplified | Any | Any | High | |
| 4 | <365 d | Not amplified | Any | Any | Intermediate | |
| 4 | 365–<547 days | Amplified | Any | Any | High | |
| 4 | 365–<547 days | Any | DI = 1 | Any | High | |
| 4 | 365–<547 days | Any | Any | Unfavorable | High | |
| 4 | 365–<547 days | Not amplified | DI > 1 | Favorable | Intermediate | |
| 4 | >547 days | Any | Any | Any | High | |
| 4S | <365 days | Not amplified | DI > 1 | Favorable | Asymptomatic | Low |
| 4S | <365 days | Not amplified | DI = 1 | Any | Asymptomatic or symptomatic | Intermediate |
| 4S | <365 days | Missing | Missing | Missing | Too sick for biopsy | Intermediate |
| 4S | <365 days | Not amplified | Any | Any | Symptomatic | Intermediate |
| 4S | <365 days | Not amplified | Any | Unfavorable | Asymptomatic or symptomatic | Intermediate |
| 4S | <365 days | Amplified | Any | Any | Asymptomatic or symptomatic | High |
* Modified schema under development replacing INSS with INRGSS. Reprinted with permission. © 2018 American Society of Clinical Oncology. All rights reserved. Naranjo, A. et al.: J Clin Oncol Clinical Cancer Informatics, Vol. (2), 2018: page 14.